AstraZeneca said the experimental vaccine prevented on average 70% of Covid-19 cases. The US regulator, the Food and Drug Administration (FDA), has not commented on AstraZeneca's vaccine trial results. The regulatory process has nonetheless been clouded, according to experts, who note crucial gaps in the data AstraZeneca has made public so far. Beyond headline efficacy rates, AstraZeneca's data release gave little for scientists to work on. By contrast, Moderna has rallied 22% since releasing its vaccine trial data on 16 November and Pfizer and BioNTech are up 6% and 14% respectively since announcing their successful data on 9 November.

Source: News 24 November 26, 2020 17:59 UTC